Nom du produit:2-((5-Bromopyrimidin-2-yl)oxy)ethan-1-ol

IUPAC Name:2-[(5-bromopyrimidin-2-yl)oxy]ethan-1-ol

CAS:1246922-88-2
Formule moléculaire:C6H7BrN2O2
Pureté:95%+
Numéro de catalogue:CM337104
Poids moléculaire:219.04

Unité d'emballage Stock disponible Prix($) Quantité
CM337104-5g 1-2 Weeks ƎǶȐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1246922-88-2
Formule moléculaire:C6H7BrN2O2
Point de fusion:-
Code SMILES:OCCOC1=NC=C(Br)C=N1
Densité:
Numéro de catalogue:CM337104
Poids moléculaire:219.04
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Aprocitentan
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023.
Aprocitentan is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
A new drug application (NDA) for aprocitentan was accepted for review by the US FDA.

Related Products